WO2002058672A2 - Microparticles of biodegradable polymer encapsulating a biologically active substance - Google Patents
Microparticles of biodegradable polymer encapsulating a biologically active substance Download PDFInfo
- Publication number
- WO2002058672A2 WO2002058672A2 PCT/CH2002/000048 CH0200048W WO02058672A2 WO 2002058672 A2 WO2002058672 A2 WO 2002058672A2 CH 0200048 W CH0200048 W CH 0200048W WO 02058672 A2 WO02058672 A2 WO 02058672A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- microparticles
- water
- active substance
- organic
- biologically active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
Definitions
- BIODEGRADABLE POLYMER ENCAPSULATING A BIOLOGICALLY ACTIVE SUBSTANCE AND SUSTAINED RELEASE PHARMACEUTICAL FORMULATIONS CONTAINING SAME.
- the present invention relates to novel microparticles of biodegradable polymer encapsulating a water-soluble or water-insoluble biologically active substance, a method for preparing same and sustained release pharmaceutical formulation comprising those microparticles.
- microparticles Many different methods of preparation of microparticles are described in the literature (Herrmann et al., European Journal of Pharmaceutics and Biopharmaceutics 45 (1998) 75-82).
- the methods presently used for the preparation of microparticles from hydrophobic polymers generally are organic phase separation and solvent removal techniques.
- the solvent removal techniques can be divided into solvent evaporation, solvent extraction, spray drying and supercritical fluid technology.
- solvent evaporation or solvent extraction techniques a drug containing organic polymer solution is emulsified into an aqueous or another organic solution. The drug is dissolved, dispersed or emulsified in the inner organic polymer solution.
- EP 0 052 105 B2 (Syntex) describes a microcapsule prepared by the phase separation technique using a coacervation agent such as mineral oils and vegetable oils.
- EP 0 145 240 B1 discloses a method for encapsulating a water-soluble compound by thickening the inner phase of a W/O emulsion, building a W/O/W and subjecting the emulsion to an "in water drying" process.
- This method brings different drawbacks such as: the necessity of using a thickening agent to retain the drug, and the multi-step procedure including two emulsification steps and the "in water drying" step.
- EP 0 190 833 B1 (Takeda) describes a method for encapsulating a water-soluble drug in microcapsules by increasing the viscosity of a primary W/O emulsion to 150-5,000 cp (by the procedure of increasing the polymer concentration in the organic phase or by adjusting the temperatures) prior to formation of a second W/O/W emulsion which is then subjected to "in water drying".
- the drawbacks of this procedure are the complexity of the necessary steps, including formation of two emulsions (W/O and W/O/W) one after the other, and the step of "in-water drying".
- US 5,407,609 (Tice/SRI) describes a microencapsulation process for highly water-soluble agents. This process involves the distinct steps of forming a primary O/W emulsion, the external aqueous phase being preferably saturated with polymer solvent. This O/W emulsion is then poured to a large volume of extraction medium in order to extract immediately the solvent. The drawback of this method is that the O/W emulsion is formed in the presence of the organic solvent in a small volume. The solvent is subsequently removed by extraction in a large aqueous volume. The polymeric droplets are prevented to harden in the primary emulsion, allowing the migration of the drug into the external phase.
- WO 95/11008 (Genentech) describes a method for the encapsulation of adjuvants into microspheres. The process comprises the three distinct steps of preparing a primary W/O emulsion, followed by the production of a W/O/W and finally the hardening of the microspheres by extraction of the solvent. As already mentioned above, the drawback of such a method is the complication due to a multi-step procedure separating droplet production from solvent elimination.
- EP 0 779 072 A1 (Takeda) describes an "in-water drying" method used for the removal of solvent after production of a W/O/W or a O/W emulsion. It is mentioned that the O/W method is preferable for active substances insoluble or sparingly soluble in water.
- WO 00/62761 discloses a method for the preparation of microparticles encapsulating water-soluble biologically active substances with an extremely high encapsulation rate thanks to the optimal reduction of diffusion for the substance to be encapsulated. That method comprises the steps of first incorporating a biodegradable polymer in an organic liquid phase comprising at least one organic non-water miscible solvent, then pouring said organic phase being into an aqueous liquid phase having a volume which is sufficient to dissolve said organic solvent, said aqueous phase containing a surfactant, and homogenizing the resulting organic/aqueous phase in order to perform in one single step the microparticle formation and the organic solvent removal.
- the microparticles are collected at the end of the homogenization step by filtration and then vacuum dried at room temperature (see Examples 1 to 6).
- microparticles collected at the end of the homogenization step are suspended without vacuum- drying thereof in a lyophilisation medium, yields novel microparticles of compartmentalized structure: they are non porous microparticles of irregular spheroidal shapes wherein pocket microparticles contain microparticles of smaller size, the active substance being evenly distributed within the polymer matrix.
- those microparticles Nevertheless due to that compartmentalized structure and/or the low level diffusion external to the microparticles during the preparation process thereof, those microparticles have the advantageous property of releasing the active substance in a regular and slow manner. When the core loading of active substance is below a threshold value, those microparticles show no or a very low burst, probably due to a molecular dispersion of the active principle within the polymer matrix. Other novel microparticles of similar structure having those advantageous properties are obtained when performing the same sequence of steps with a water-insoluble biologically active substance.
- the invention thus concerns microparticles of biodegradable polymer encapsulating a water-soluble or water-insoluble biologically active substance, wherein pocket microparticles contain microparticles of smaller size, wherein said microparticles are obtainable by a method comprising
- the organic liquid phase may be prepared by dissolving or dispersing that substance in a volume of water, dissolving the biodegradable polymer in a 10 to 100 larger volume of non-water miscible organic solvent showing a low solubility in water, and mixing under vigorous agitation the aqueous and the organic solutions obtained, e.g. by pouring the aqueous solution into the organic solution and homogenizing the mixture at high rotation speed, for example using a Polytron PT 6100 (PT-DA 3020/2TM shaft) at 10 000 to 30 000 rpm.
- the organic liquid phase may be prepared by dissolving that substance together with the biodegradable polymer in a non-water miscible organic solvent showing a low solubility in water.
- step (a) One of the specific features in the process for preparing the microparticles is that no stable emulsion comprising organic solvent droplets occurs in step (a) when pouring the organic liquid phase into an aqueous liquid phase of sufficient volume to dissolve said organic solvent. Avoiding such a step results in a better retention of the biologically active substance and a direct harvesting of the microparticles after their formation.
- the water-soluble biologically active substance is quickly kept inside the microparticles which have an impermeable wall. Thereby any diffusion of the active substance external to the microparticles is at a low level, the encapsulation rate is very high and the amount of the biologically active substance on the surface of the microparticles is minimal. Hence a release of the active substance in a regular and slow manner.
- the core loading is low enough for a very fine dispersion, probably a molecular dispersion, of the active principle within the polymer matrix, those microparticles show no or a very low burst. Those microparticles with no or a very low burst may show an initial release of the active substance of less than 10 % during the first 24 hours, or even below 3% during the first 48 hours.
- the organic solvents used in the process of the present invention are non-water miscible solvents showing a low solubility in water such as esters (e.g. ethyl acetate, butyl acetate), halogenated hydrocarbons (e.g. dichloromethane, chloroform, carbon tetrachloride, chloroethane, dichloroethane, trichloroethane), ethers (e.g. ethyl ether, isopropyl ether), aromatic hydrocarbons (e.g. benzene, toluene, xylene), carbonates (e.g. diethyl carbonate), or the like.
- esters e.g. ethyl acetate, butyl acetate
- halogenated hydrocarbons e.g. dichloromethane, chloroform, carbon tetrachloride, chloroethane, dichloroethane, trichloroethane
- solvents are generally classified by the person skilled in the art as non-water miscible solvent, they are actually sparingly miscible in water, having a low solubility in water.
- solubility is respectively 8.70% and 1.32% (by weight) in water at 20-25°C (see A.K. Doolittle Ed., Properties of individual solvents, in The technology of solvents and plasticizers, chpt. 12. Wiley, New York, 1954, pp. 492-742).
- One of the preferred solvent is ethyl acetate.
- organic solvents can be used alone or in mixtures of two or more different solvents.
- the volume of the aqueous liquid phase must be sufficient to dissolve, or extract, the total amount of organic solvent used. If this is not the case, the microparticles cannot be sufficiently hardened. Those "soft" microparticles may therefore melt among each other during the filtration process.
- the amount of organic solvent is kept as low as possible to get a viscous organic phase and to minimize the necessary volume of the aqueous phase.
- the volume of the aqueous phase is chosen to be capable of dissolving at least the complete amount of organic solvent.
- the maximal value of the ratio solvent water (w/w) in the present invention should therefore preferably be 0.087 and 0.013 for ethyl acetate and dichloromethane respectively.
- the ratio ethyl acetate/aqueous phase ranges from 0.007 to 0.06. The encapsulating efficiency improves if the volume of aqueous phase increases.
- a surfactant is added to the aqueous phase in order to keep the precipitating biodegradable polymer in fine independent particles.
- An ideal surfactant gives a viscosity to the aqueous phase that approaches the viscosity of the organic phase.
- An electrolyte may also be optionally added to the aqueous solution to create repulsion between the particles and preventing aggregation.
- sodium chloride is used in the aqueous phase and leads to a higher encapsulating efficiency.
- the aqueous solution can also be buffered to obtain good pH conditions for the drug concerning stability and release.
- the encapsulation efficiency is increased when using cold solutions, by optimizing the solubility of the solvent in water, by reducing the aqueous solubility of the drug, and by slowing down its diffusion.
- the present invention achieves the effect of further reducing the already small amount of diffusion of internal particle substances to the exterior.
- a water-soluble biologically active substance is dispersed as such or as an aqueous solution into one of the above-mentioned non-miscible organic solvent.
- the biologically active substance is present in solid state in the organic phase during the entrapment procedure, thus slowing down the solubilisation into the aqueous liquid phase.
- the thus obtained liquid organic phase containing the biologically active substance is used to dissolve the biodegradable polymer.
- the appropriate biodegradable polymers comprise poly(lactides), poly(glycolides), copolymers thereof or other biodegradable polymers such as other aliphatic polymers, polycitric acid, polymalic acid, polysuccinates, polyfumarates, poly- hydroxybutyrates, polycaprolactones, polycarbonates, polyesteramides, poly- anhydrides, poly(amino acids), polyorthoesters, polycyano-acrylates, polyetheresters, poly(dioxanone)s, copolymers of polyethylene glycol (PEG), polyorthoesters, biodegradable polyurethanes, polyphosphazenes.
- biodegradable polymers such as other aliphatic polymers, polycitric acid, polymalic acid, polysuccinates, polyfumarates, poly- hydroxybutyrates, polycaprolactones, polycarbonates, polyesteramides, poly- anhydrides, poly(amino acids), poly
- biocompatible polymers are polyacrylic acid, polymethacrylic acid, acrylic acid-methacrylic acid copolymers, dextran stearate, ethylcellulose, acetyl- cellulose, nitrocellulose, etc. These polymers may be homopolymers or copolymers of two or more monomers, or mixtures of the polymers.
- a particularly interesting biodegradable polymer is poly(D-L-lactide-co-glycolide).
- the biologically active substance and the polymer can also be incorporated in separate organic phases.
- the polymer is dissolved in another above-mentioned organic non-water miscible solvent.
- Preferred solvents include ethyl acetate or dichloromethane. More preferred is when the solvent used to dissolve the polymer is the same solvent as that use for incorporating the biologically active substance.
- the thus obtained separated organic phases are poured together to form a homogenous organic phase before addition to the aqueous phase.
- the biologically active substance and/or the biodegradable polymer is not or is only slightly soluble in one of the above-mentioned solvent, for instance in the preferred solvent ethyl acetate, a sufficient amount of co-solvents such those comprised among the family of benzyl alcohol, DMSO, DMF, ethyl alcohol, methyl alcohol, acetonitrile and the like, may optionally be used for that purpose.
- a better encapsulating efficiency can be achieved by an appropriate setting of the physic chemical parameters such as surfactant capacity, viscosity, temperature, ionic strength, pH and buffering potential during the homogenization of the organic inner phase into the aqueous phase.
- the amount of solvent used to dissolve the biodegradable polymer is kept to a minimum in order to be soluble as quickly as possible (most preferably at once) in the aqueous phase. If the amount of solvent is high, the amount of aqueous phase has to be too large on a practical point of view.
- the concentration of polymer in the organic phase is adjusted to 5-90% (by weight), preferably between about 10 and 50%, depending on the polymer and solvent used.
- the viscosity of this phase may be increased.
- the viscosity of the polymer solution may be comprised between 1000 and 40,000 centipoise (cp) (Brookfield viscosity), more preferably between 2,000 and 30,000 cp, even more preferably between 3,000 and 20,000 cp.
- cp centipoise
- the solubility of the solvent in the aqueous phase is increased by lowering the temperature of both the organic and the aqueous phases, accelerating the solvent migration and therefore also the encapsulation rate.
- the temperature of the organic phase ranges between about -10°C and 30°C, and preferably between about 0°C and 10°C.
- the temperature ranges preferably between about 2°C and 5°C.
- the temperature of the polymeric organic phase and the temperature of the aqueous phase are the same or different and are adjusted in order to increase the solubility of the solvent in the aqueous phase.
- the obtained organic phase for use as the inner polymer and biologically active substance containing phase is added to a aqueous outer phase under a homogenization procedure to give microparticles.
- a method of creating dispersion is used.
- This dispersion can be realized for example with any apparatus capable of shaking, mixing, stirring, homogenizing or ultrasonicating.
- surfactants such as for example an anionic surfactant (e.g. sodium oleate, sodium stearate, sodium lauryl sulfate), a nonionic surfactant (e.g. polyoxyethylene-sorbitan fatty acid ester (Tween 80, Tween 60, products available from Atlas Powder Co, U.S.A.), a polyoxyethylene castor oil derivative (HCO-60, HCO-50, products available from Nikko Chemicals, Japan)), polyvinyl pyrrolidone, polyvinyl alcohol, carboxymethyl-cellulose, lecithin or gelatine.
- anionic surfactant e.g. sodium oleate, sodium stearate, sodium lauryl sulfate
- a nonionic surfactant e.g. polyoxyethylene-sorbitan fatty acid ester (Tween 80, Tween 60, products available from Atlas Powder Co, U.S.A.), a polyoxyethylene castor oil derivative (HCO-60, HCO-50
- a surfactant comprised among the family of anionic, non-ionic agents or other agents capable of reducing the surface tension of the polymeric dispersion can be added.
- nonionic surfactants such as Tween (for example Tween 80), anionic surfactants, nonionic surfactant like polyvinyl alcohol or others.
- Tween for example Tween 80
- anionic surfactants nonionic surfactant like polyvinyl alcohol or others.
- These surfactants can, in general, be used alone or in combination with other suitable surfactants.
- the concentration of the surfactant is selected in order to disperse and stabilize the polymer particles, and possibly also to give a viscosity approaching the viscosity of the organic phase.
- the preferred concentration of the surfactant in the aqueous phase ranges therefore between about 0.01-50% (by weight), preferably between about 5 and 30%.
- the viscosity depending on the surfactant used and on its concentration ranges between about 1 ,000-8,000 cp (Brookfield viscosity), preferably about 3,000-5,000 cp.
- Optionally salts comprised among the family of sodium chloride, potassium chloride, carbonates, phosphates and the like can be added to the aqueous phase to adjust ionic strength and to create a Zeta potential between the polymer particles, leading to particle repulsion.
- Additional buffering agents may be added to the aqueous phase to maintain a specific pH.
- the internal aqueous phase may be supplemented with a pH regulator for retaining stability or solubility of the biologically active substance, such as carbonic acid, acetic acid, oxalic acid, citric acid, phosphoric acid, hydrochloric acid, sodium hydroxide, arginine, lysine or a salt thereof.
- the pH of the formulations of this invention is generally about 5 to 8, preferably about 6.5 to 7.5.
- the temperature of the aqueous phase can be adjusted to the temperature of the inner organic phase.
- the temperature range is from about -10°C to 30°C, more preferably between 0° and 10° C and even more preferably from between 2°C and 5°C.
- the microparticles of the present invention can be prepared in any desired size, ranging from 1 ⁇ m to about 500 ⁇ m, by varying the parameters such as polymer type and concentration in the organic phase, volumes and temperature of the organic and aqueous phase, surfactant type and concentration, homogenization time and speed.
- the mean particle size of the microparticles ranges generally from 10 to 200 ⁇ m, more preferably from 20 to 200 ⁇ m, even more preferably from 30 to 150 ⁇ m.
- the encapsulated soluble substance is a peptide, a polypeptide, a protein and their related pharmaceutically acceptable salts.
- the salt of peptide is suitably a pharmacologically acceptable salt.
- Such salts include salts formed with inorganic acids (e.g. hydrochloric acid, sulfuric acid, nitric acid), organic acids (e.g. carbonic acid, bicarbonic acid, succinic acid, acetic acid, propionic acid, trifluoroacetic acid) etc.
- the salt of peptide is a salt formed with an organic acid (e.g.
- anticancer drugs such as actinomycin D, bleomycin, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, doxorubicin, estramustine, etoposide, floxuridine, fludarabine, fluorouracil, hexamethylmelamine, hydroxyurea, idarubicin, ifosfamide, asparaginase, lomustine, mechlorethamine, melphalan, mercaptopurine, methotrexate, mithramycin, mitomycin C, mitotane, mitozantrone, oxaliplatine, pentostatin, procarbazine, streptozocin, teniposide, thioguanine, thiopeta, vinblastine, vincristine, , an aroma
- analgesics and antiinflammatory agents include acetaminophen, acetylsalicylic acid, methylprodnisolone, ibuprofen diclofenac sodium, indomethacin sodium, flufenamate sodium, pethidine hydrochloride, levorphanol tartrate, morphine hydrochloride, oxymorphone and the like; anesthetics such as xylocaine and the like; antiulcer agents include metoclopramide, ranitidine hydrochloride, cimetidine hydrochloride, histidine hydrochloride, and the like anorexics such as dexedrine, phendimetrazine tartrate, and the like; antitussives such as noscapine hydrochloride, dihydrocodeine phosphate, ephedrine hydrochloride, terbutaline sulfate, isopreterenol hydrochloride, salbutamol sulfate
- sedatives such as chlorpromazine hydrochloride, scopolamine methylbromide, antihistaminics such as diphenhydramine hydrochloride, ketotifen fumarate, chlorpheniramine maleate, methoxy-phenamine hydrochloride and the like.
- cardiotonics such as etilefrine hydrochloride, aminophylline and the like; antiasthmatics such as terbutaline sulfate, theophylline, ephedrine, cetirizin and the like; antifungals such as amphotericin B, nystatin, ketoconazole, and the like; antiosteopotic agents such as bisphosphonates, e.g.
- alendronate antiarrhytmic agents such as propranolol hydrochloride, alprenolol hydrochloride, bufetolol hydrochloride, oxyprenolol hydrochloride and the like; antitubercular agents such as isoniazid, ethambutol, and the like; hypotensive, diuretic agents such as captopril, ecarazine, mecamylamine hydrochloride, clonidine hydrochloride, bunitrolol hydrochloride and the like; hormones such as prednisolone sodium sulfate, betamethasone sodium phosphate, hexestrol phosphate, dexamethasone sodium sulfate and the like; antigens from bacteria, viruses or cancers, antidiabetics such as glipizide, phenformin hydrochloride, buformin hydrochloride, glymidine sodium, methformin, and the like; cardiovascular agents such
- Preferred substances include Tamoxiphen, 4-OH Tamoxiphen, a derivative thereof, a non-soluble LHRH derivative such as T ptorelin pamoate and a non- soluble somatostatin derivative such as OctreotideTM, LanreotideTM or vapreotide pamoate.
- the invention also concerns a sustained release pharmaceutical formulation which comprises a suspension of the above microparticles in a pharmaceutically acceptable vehicle.
- a sustained release pharmaceutical formulation which comprises a suspension of the above microparticles in a pharmaceutically acceptable vehicle.
- the initial release of the active substance during the first 24 hours is less than 10 %. More preferably the initial release during the first 48 hours is less than 3 %.
- the invention also relates to a method of preparing the above microparticles, which comprises
- Figures 1A, 1 B, 3 and 4 are curves representing the in vitro release profiles of batches (49, 53 and 56) and (58, 59 and 60) of Triptorelin acetate encapsulating microparticles, batch 4 of Tamoxifen encapsulating microparticles, and batch 5 of 4-OH-Tamoxiphen, respectively.
- Figure 2A represents the variation of the cum AUC (cumulated area under the curve) of the Triptorelin acetate level for batches 56 and 69 of Triptorelin acetate as a function of time for rats, injected on day 1 with a suspension of Triptorelin acetate encapsulating microparticles of batches 56 and 69.
- Figure 2B represents the va ⁇ ation of serum testosterone levels as a function of time for rats previously housed close to female rats, injected on day 1 with a suspension of Triptorelin acetate encapsulating microparticles of batches 56 and 57 and non treated rats as a control.
- Figures 5A and 5B represent scanning electron microscopy photographs of a Triptorelin acetate encapsulating microparticle of batch 57. Those photographs show a primary polymeric non porous pocket microparticle containing secondary polymeric microparticles of smaller size, the active substance being evenly distributed within the polymer matrix.
- Figure 6 represents a transmission electron microscopy photograph of a Triptorelin acetate encapsulating microparticle of batch 57 cut in a thin layer. That photograph shows a polymeric non porous pocket microparticle containing secondary microparticles of smaller size.
- This w/o preparation was poured into about 8500 g of aqueous phase containing 20% (w/w) of polyoxyethylene sorbitan fatty acid ester (Tween 80) and possibly 84.4 g of sodium chloride, in a reactor kept at a temperature of 4°C.
- aqueous phase containing 20% (w/w) of polyoxyethylene sorbitan fatty acid ester (Tween 80) and possibly 84.4 g of sodium chloride
- the homogenization was performed using a Polytron PT 6100 (PT6020/2TM shaft) at 3000-3500 rpm during 5 minutes, thereby forming a suspension of microparticles 6.
- the microparticles were collected by filtration and washed with about 9 I of sterile distilled water yielding a bulk of microparticles.
- microparticles were suspended in a lyophilization medium consisting of mannitol, Tween 80 and sodium carboxy-methyl-cellullose using a magnetic rod at 200 rpm, and possibly homogenized using an IKA-T25 homogenizes at 8000 rpm during 20 minutes or at 9500 rpm during 30 minutes (batches 58-
- the obtained microparticle lyphilisate showed less than 2 % residual water.
- the entrapment efficiency was measured by UV spectrometry on the bulk of microparticles and by HPLC on the lypholisate and the particle size distribution was determined using a laser granulometer (Mastersizer®, Malvern Instruments).
- Batch 49 obtained using a reactor with a conic lower part in steps 4 and 5, no sodium chloride in step 4, no step 7, and no homogenization in step 8, showed a mean particle size of 92.5 ⁇ m and an entrapment efficiency of 81.8 % on the lyophilisate.
- Batch 53 obtained using a reactor with a conic lower part in steps 4 and 5, 84.4 g sodium chloride in step 4, no step 7, and no homogenization in step 8, showed a mean particle size of 96.1 ⁇ m and an entrapment efficiency of 75.4 % on the lyophilisate.
- Batch 56 obtained using a reactor with a conic lower part in steps 4 and 5, no sodium chloride in step 4, and step 7, and homogenization in step 8, showed a mean particle size of 70.0 ⁇ m and an entrapment efficiency of 87.7 % on the bulk.
- Batch 57 obtained using a reactor with a conic lower part in steps 4 and 5, 84.4 g sodium chlo ⁇ de in step 4, no step 7 and homogenization in step 8, showed a mean particle size of 84.3 ⁇ m and an entrapment efficiency of 91.7 % on the bulk.
- Batch 58 obtained using a reactor with a flat bottom in steps 4 and 5, no sodium chlo ⁇ de in step 4, no step 7, and homogenization in step 8, showed a mean particle size of 39.2 ⁇ m.
- Batch 59 obtained using a reactor with a conic bottom in steps 4 and 5, no sodium chloride in step 4, no step 7, and homogenization in step 8, showed a mean particle size of 59.3 ⁇ m.
- Batch 60 obtained as batch 59 but with a different PLGA 50/50 having a lower average molecular weight, showed a mean particle size of 87.1 ⁇ m.
- the lyophilisate microparticles were put in a methanol/water mixture under stirring at 200 rpm at 37 °C in a test representative of the physiological conditions in the human body. Samples from this mixture were analyzed as a function of time by HPLC.
- Example 3A Effect of injection of Triptorelin acetate encapsulating microparticles in rats on the serum Triptorelin acetate levels
- Protocol 6 adult male rats are given an intramuscular injection of a suspension of Triptorelin acetate encapsulating microparticles in sterile distilled water. Blood samples are then collected regularly from day 1 (day of the injection) through day 35 for determining of Triptorelin acetate levels.
- Figure 2A represents the variation of the cum AUC (cumulated area under the curve) of the Triptorelin acetate level for batches 56 and 69 of Triptorelin acetate as a function of time.
- That curve shows that the cum AUC, i.e. the burst, is less than 10 % after 24 hours and the variation of that parameter is linear until day 35.
- Example 3B Effect of injection of Triptorelin acetate encapsulating microparticles in rats on the serum testosterone levels
- Batch 4 of Tamoxifen encapsulating microparticles was prepared using a sequence of steps similar to that described in Example 1 for batch 56, with the main difference that in the first step water-insoluble Tamoxifen is dissolved in the ethyl acetate solution together with the PLGA 50/50 having a average molecular weight of 45,000, the following steps being very similar to steps 4 to 8.
- That batch showed a mean particle size of 49.6 ⁇ m as determined by laser granulometry and an encapsulation efficiency of 82.8 %.
- the lyophilisate microparticles were put in a methanol/water mixture under stirring at 200 rpm at 37 °C in a test representative of the physiological conditions in the human body. Samples from this mixture were analyzed as a function of time by HPLC.
- That curve shows a release of the therapeutically active substance of less than 10 % during the first 48 hours, and a linear release up to 1 month.
- Batch 5 of the Z isomer of 4-OH-Tamoxifen encapsulating microparticles was prepared using a sequence of steps similar to that described in Example 1 for batch 56, with the main difference that in the first step water-insoluble 4-OH- Tamoxifen is dissolved in the ethyl acetate solution together with the PLGA 50/50 having a average molecular weight of 45,000, the following steps being very similar to steps 4 to 8.
- That batch showed a mean particle size of 53.98 ⁇ m as determined by laser granulometry and an encapsulation efficiency of 66.92 % on the lyophilisate.
- Example 2 An in vitro release test similar to that described in Example 2 showed a release of the therapeutically active substance of about 9.2 %, i.e. a burst of less than 10 % during the first 24 hours, and a linear release up to 500 hours (see Figure 4).
- the aqueous phase solution was poured into the organic phase solution and the mixture was homogenized using a Polytron PT 6100 (PT-DA 3020/2TM shaft) at 20,000 rpm during 2 minutes.
- This w/o preparation was poured into about 1687.5 g of aqueous phase containing 20% (w/w) of polyoxyethylene sorbitan fatty acid ester (Tween 80) in a reactor kept at a temperature of 4°C. 5.
- the homogenization was performed using a Polytron PT 6100 (PT6060/2TM shaft) at 3,000 rpm during 5 minutes, thereby forming a suspension microparticles.
- microparticles were collected by filtration and washed with bout 1.7 I of sterile distilled water yielding a bulk of microparticles.
- microparticles were suspended in a lyophilization medium consisting of mannitol and sodium carboxy-methyl-cellulose (and possibly Tween 80) using an IKA T25 homogenizes at 9,500 rpm during 30 minutes.
- the suspension was poured on a tray and freeze-dried.
- freeze-dried microparticles were sieved on 106 ⁇ m.
- the obtained freeze-dried microparticles showed less than 2% residual water.
- the entrapment efficiency was measured by HPLC on the freeze-dried microparticles and the particles size distribution was determined using a laser granulometer (MastersizerTM, Malvern Instruments).
- An in vitro release test similar to that described in Example 2 showed a release of the therapeutically active substance of less than 10 % during the first 24 hours, and a linear release up to 500 hours.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02715353A EP1353648A2 (en) | 2001-01-26 | 2002-01-28 | Microparticles of biodegradable polymer encapsulating a biologically active substance |
JP2002559006A JP2004517146A (en) | 2001-01-26 | 2002-01-28 | Bioactive substance encapsulated biodegradable polymer microparticles and sustained-release pharmaceutical formulation containing the microparticles |
CA002435415A CA2435415A1 (en) | 2001-01-26 | 2002-01-28 | Microparticles of biodegradable polymer encapsulating a biologically active substance |
US10/250,857 US20040052855A1 (en) | 2001-01-26 | 2002-01-28 | Microparticles of biodegradable polymer encapsulating a biologically active substance and sustained release pharmaceutical formulations containing same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CH2001/000064 WO2002058671A1 (en) | 2001-01-26 | 2001-01-26 | Burst free pharmaceutical microparticules |
CHPCT/CH01/00064 | 2001-01-26 | ||
IB0101370 | 2001-07-31 | ||
IBPCT/IB01/01370 | 2001-07-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002058672A2 true WO2002058672A2 (en) | 2002-08-01 |
WO2002058672A3 WO2002058672A3 (en) | 2002-12-19 |
Family
ID=25705676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CH2002/000048 WO2002058672A2 (en) | 2001-01-26 | 2002-01-28 | Microparticles of biodegradable polymer encapsulating a biologically active substance |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA2435415A1 (en) |
WO (1) | WO2002058672A2 (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2865938A1 (en) * | 2004-02-05 | 2005-08-12 | Sod Conseils Rech Applic | Parenteral delayed release solid formulation, useful to treat prostrate cancer comprises triptorelin acetate and excipients comprising polymers and/or co polymers of lactic acid or glycolic acid |
FR2869801A1 (en) * | 2004-05-05 | 2005-11-11 | Ethypharm Sa | PROCESS FOR THE PREPARATION OF PROLONGED RELEASE COMPOSITIONS AND USE THEREOF FOR THE TREATMENT OF CHRONIC AFFECTIONS OF THE CENTRAL NERVOUS SYSTEM (CNS) |
WO2008041246A2 (en) * | 2006-10-05 | 2008-04-10 | Panacea Biotec Ltd. | Injectable depot composition and its' process of preparation |
EP2088154A1 (en) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US8080562B2 (en) | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
WO2012151343A1 (en) | 2011-05-04 | 2012-11-08 | Balance Therapeutics, Inc. | Pentylenetetrazole derivatives |
US8378105B2 (en) | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
US8592450B2 (en) | 2005-05-17 | 2013-11-26 | Sarcode Bioscience Inc. | Compositions and methods for treatment of eye disorders |
WO2014131024A2 (en) | 2013-02-25 | 2014-08-28 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
US8871269B2 (en) | 2003-07-15 | 2014-10-28 | Evonik Corporation | Method for the preparation of controlled release formulations |
US8900636B2 (en) * | 2003-07-23 | 2014-12-02 | Evonik Corporation | Controlled release compositions |
EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8916196B2 (en) | 2003-04-10 | 2014-12-23 | Evonik Corporation | Method for the production of emulsion-based microparticles |
WO2015054649A2 (en) | 2013-10-10 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions |
US9085553B2 (en) | 2012-07-25 | 2015-07-21 | SARcode Bioscience, Inc. | LFA-1 inhibitor and methods of preparation and polymorph thereof |
US9216174B2 (en) | 2003-11-05 | 2015-12-22 | Sarcode Bioscience Inc. | Modulators of cellular adhesion |
EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2017123634A1 (en) | 2016-01-11 | 2017-07-20 | Synergy Pharmaceuticals, Inc. | Formulations and methods for treating ulcerative colitis |
EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
US10960087B2 (en) | 2007-10-19 | 2021-03-30 | Novartis Ag | Compositions and methods for treatment of diabetic retinopathy |
IT202000017191A1 (en) | 2020-07-15 | 2022-01-15 | Xbrane Biopharma Ab | WATERLESS PROCESS FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR A LONGER AND CONTROLLED RELEASE OF TRIPTORELIN OR A SALT ITS |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0601799A1 (en) * | 1992-12-07 | 1994-06-15 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
WO2000062761A1 (en) * | 1999-04-15 | 2000-10-26 | Debio Recherche Pharmaceutique S.A. | Process for microencapsulation of water soluble substances |
WO2002028386A1 (en) * | 2000-10-03 | 2002-04-11 | Debiopharm S.A. | Method for preparing microspheres containing a water-soluble substance |
WO2002058671A1 (en) * | 2001-01-26 | 2002-08-01 | Debio Recherche Pharmaceutique S.A. | Burst free pharmaceutical microparticules |
-
2002
- 2002-01-28 CA CA002435415A patent/CA2435415A1/en not_active Abandoned
- 2002-01-28 WO PCT/CH2002/000048 patent/WO2002058672A2/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0601799A1 (en) * | 1992-12-07 | 1994-06-15 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
WO2000062761A1 (en) * | 1999-04-15 | 2000-10-26 | Debio Recherche Pharmaceutique S.A. | Process for microencapsulation of water soluble substances |
WO2002028386A1 (en) * | 2000-10-03 | 2002-04-11 | Debiopharm S.A. | Method for preparing microspheres containing a water-soluble substance |
WO2002058671A1 (en) * | 2001-01-26 | 2002-08-01 | Debio Recherche Pharmaceutique S.A. | Burst free pharmaceutical microparticules |
Non-Patent Citations (2)
Title |
---|
BLANCO-PRÍETO M J ET AL: "In vitro and in vivo evaluation of a somatostatin analogue released from PLGA microspheres." JOURNAL OF CONTROLLED RELEASE: OFFICIAL JOURNAL OF THE CONTROLLED RELEASE SOCIETY. NETHERLANDS 15 JUN 2000, vol. 67, no. 1, 15 June 2000 (2000-06-15), pages 19-28, XP002216451 ISSN: 0168-3659 * |
WANG H T ET AL: "INFLUENCE OF FORMULATION METHODS ON THE IN VITRO CONTROLLED RELEASE OF PROTEIN FROM POLY (ESTER) MICROSPHERES" JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 17, no. 1, 1 September 1991 (1991-09-01), pages 23-31, XP000223264 ISSN: 0168-3659 * |
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8916196B2 (en) | 2003-04-10 | 2014-12-23 | Evonik Corporation | Method for the production of emulsion-based microparticles |
US10272044B2 (en) | 2003-04-10 | 2019-04-30 | Evonik Corporation | Method for the production of emulsion-based microparticles |
US8871269B2 (en) | 2003-07-15 | 2014-10-28 | Evonik Corporation | Method for the preparation of controlled release formulations |
US8900636B2 (en) * | 2003-07-23 | 2014-12-02 | Evonik Corporation | Controlled release compositions |
US9216174B2 (en) | 2003-11-05 | 2015-12-22 | Sarcode Bioscience Inc. | Modulators of cellular adhesion |
US9248126B2 (en) | 2003-11-05 | 2016-02-02 | Sarcode Bioscience Inc. | Modulators of cellular adhesion |
FR2865938A1 (en) * | 2004-02-05 | 2005-08-12 | Sod Conseils Rech Applic | Parenteral delayed release solid formulation, useful to treat prostrate cancer comprises triptorelin acetate and excipients comprising polymers and/or co polymers of lactic acid or glycolic acid |
WO2005082418A1 (en) * | 2004-02-05 | 2005-09-09 | Societe De Conseils De Recherche Et D'applications Scientifiques (S.C.R.A.S.) | Long-acting solid formulation comprising triptorelin acetate |
EP2088154A1 (en) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
FR2869801A1 (en) * | 2004-05-05 | 2005-11-11 | Ethypharm Sa | PROCESS FOR THE PREPARATION OF PROLONGED RELEASE COMPOSITIONS AND USE THEREOF FOR THE TREATMENT OF CHRONIC AFFECTIONS OF THE CENTRAL NERVOUS SYSTEM (CNS) |
WO2005120435A2 (en) * | 2004-05-05 | 2005-12-22 | Ethypharm | Method for preparing sustained release compositions and the use of said compositions for treating chronic diseases of central nervous system (cns) |
WO2005120435A3 (en) * | 2004-05-05 | 2006-05-26 | Ethypharm Sa | Method for preparing sustained release compositions and the use of said compositions for treating chronic diseases of central nervous system (cns) |
US8592450B2 (en) | 2005-05-17 | 2013-11-26 | Sarcode Bioscience Inc. | Compositions and methods for treatment of eye disorders |
US9045458B2 (en) | 2005-05-17 | 2015-06-02 | Sarcode Bioscience Inc. | Compositions and methods for treatment |
US9051297B2 (en) | 2005-05-17 | 2015-06-09 | Sarcode Bioscience Inc. | Compositions and methods for treatment |
US8758776B2 (en) | 2005-05-17 | 2014-06-24 | Sarcode Bioscience Inc. | Compositions and methods for treatment |
US8771715B2 (en) | 2005-05-17 | 2014-07-08 | Sarcode Bioscience Inc. | Compositions and methods for treatment |
US10188641B2 (en) | 2005-05-17 | 2019-01-29 | Sarcode Bioscience Inc. | Compositions and methods for treatment |
US9045457B2 (en) | 2005-05-17 | 2015-06-02 | Sarcode Bioscience Inc. | Compositions and methods for treatment |
WO2008041246A3 (en) * | 2006-10-05 | 2008-05-29 | Panacea Biotec Ltd | Injectable depot composition and its' process of preparation |
WO2008041246A2 (en) * | 2006-10-05 | 2008-04-10 | Panacea Biotec Ltd. | Injectable depot composition and its' process of preparation |
EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US10960087B2 (en) | 2007-10-19 | 2021-03-30 | Novartis Ag | Compositions and methods for treatment of diabetic retinopathy |
US8871935B2 (en) | 2008-04-15 | 2014-10-28 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
US8080562B2 (en) | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
US11028077B2 (en) | 2008-04-15 | 2021-06-08 | Novartis Pharmaceuticals Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
US8367701B2 (en) | 2008-04-15 | 2013-02-05 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
US8378105B2 (en) | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
US9353088B2 (en) | 2009-10-21 | 2016-05-31 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
US8927574B2 (en) | 2009-10-21 | 2015-01-06 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
US9890141B2 (en) | 2009-10-21 | 2018-02-13 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
EP2923706A1 (en) | 2009-12-03 | 2015-09-30 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia |
WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2012151343A1 (en) | 2011-05-04 | 2012-11-08 | Balance Therapeutics, Inc. | Pentylenetetrazole derivatives |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
EP4309673A2 (en) | 2012-03-15 | 2024-01-24 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
EP3708179A1 (en) | 2012-03-15 | 2020-09-16 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
US9085553B2 (en) | 2012-07-25 | 2015-07-21 | SARcode Bioscience, Inc. | LFA-1 inhibitor and methods of preparation and polymorph thereof |
US10214517B2 (en) | 2012-07-25 | 2019-02-26 | Sarcode Bioscience Inc. | LFA-1 inhibitor and methods of preparation and polymorph thereof |
US10906892B2 (en) | 2012-07-25 | 2021-02-02 | Novartis Pharmaceuticals Corporation | LFA-1 inhibitor and methods of preparation and polymorph thereof |
WO2014131024A2 (en) | 2013-02-25 | 2014-08-28 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
EP3718557A2 (en) | 2013-02-25 | 2020-10-07 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
WO2015054649A2 (en) | 2013-10-10 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions |
WO2017123634A1 (en) | 2016-01-11 | 2017-07-20 | Synergy Pharmaceuticals, Inc. | Formulations and methods for treating ulcerative colitis |
IT202000017191A1 (en) | 2020-07-15 | 2022-01-15 | Xbrane Biopharma Ab | WATERLESS PROCESS FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR A LONGER AND CONTROLLED RELEASE OF TRIPTORELIN OR A SALT ITS |
WO2022013233A1 (en) | 2020-07-15 | 2022-01-20 | Xbrane Biopharma Ab | Water-free process for preparing a pharmaceutical composition for a more sustained and controlled release of triptorelin or a salt thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2002058672A3 (en) | 2002-12-19 |
CA2435415A1 (en) | 2002-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002058672A2 (en) | Microparticles of biodegradable polymer encapsulating a biologically active substance | |
EP0350246B1 (en) | Sustained release microcapsule for water soluble drug | |
EP1196148B1 (en) | Process for microencapsulation of water soluble substances | |
FI96278B (en) | Process for Preparation of a Extended Release Microcapsule of Lutinizing Hormone Hormone Release | |
US5643607A (en) | Prolonged release microcapsules | |
US5271945A (en) | Sustained release microcapsule for water soluble drug | |
EP0535937B2 (en) | Prolonged release microparticle preparation and production of the same | |
US6861064B1 (en) | Encapsulation method | |
JP3277342B2 (en) | Manufacturing method of sustained release microcapsules | |
JP2004516262A (en) | Induced phase transition method for the production of microparticles containing hydrophilic activators | |
JPH10182496A (en) | Sustained release preparation | |
US6616949B2 (en) | Process for producing microparticles | |
JPH09221417A (en) | Production of controlled release preparation for injection | |
US20040052855A1 (en) | Microparticles of biodegradable polymer encapsulating a biologically active substance and sustained release pharmaceutical formulations containing same | |
AU2002224721A1 (en) | Microparticles of biodegradable polymer encapsulating a biologically active substance | |
CA2429103A1 (en) | Process for producing microparticles | |
WO2015150942A2 (en) | Improved process for preparing microparticles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002224721 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10250857 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2435415 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002559006 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002715353 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002715353 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002715353 Country of ref document: EP |